Pharmacokinetics, dosing principles, and blood level monitoring of FK506.

No abstract is available for this paper.

• Publication year

  1994

• Venue

  Transplantation Proceedings

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 7527962
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Specific and sensitive measurement of FK506 and its metabolites in blood and urine of liver-graft recipients.

  1992cited by this paper
• Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat.

  1992cited by this paper
• Measurement of FK 506 by HPLC and isolation and characterization of its metabolites.

  1991cited by this paper
• Isolation of an immunosuppressive metabolite of FK506 generated by human microsome preparations.

  1991cited by this paper

• Monitoring Tacrolimus Trough Concentrations During the First Year After Kidney Transplantation: A National Retrospective Cohort Study

  2020cites this paper
• Impact of genetic polymorphisms on tacrolimus pharmacokinetics and the clinical outcome of renal transplantation

  2012cites this paper
• TACROLIMUS IN TRANSPLANTATION OF THE KIDNEY. COMMUNICATION 1

  2012cites this paper
• Suivi thérapeutique du tacrolimus durant les trois mois post-greffe : étude rétrospective sur la cohorte des allogreffes rénales 2010 et 2011 au CHU de Grenoble

  2011cites this paper
• CHAPTER 2 Pharmacokinetics and pharmacogenomics of tacrolimus : a review

  2008cites this paper
• Factors Affecting the Apparent Clearance of Tacrolimus in Korean Adult Liver Transplant Recipients

  2006cites this paper
• Pharmacokinetic Considerations Relating to Tacrolimus Dosing in the Elderly

  2005cites this paper
• Clinical Pharmacokinetics and Pharmacodynamics of Tacrolimus in Solid Organ Transplantation

  2004cites this paper
• Tacrolimus and cerivastatin pharmacokinetics and adverse effects after single and multiple dosing with cerivastatin in renal transplant recipients.

  2003cites this paper
• Determination of the pharmacokinetics of cerivastatin when administered in combination with sirolimus and cyclosporin A in patients with kidney transplant, and review of the relevant literature.

  2003cites this paper
• Evaluation of the Dade Behring Syva® EMIT 2000 tacrolimus assay on the Bayer Advia 1650

  2003cites this paper
• Increase in tacrolimus trough levels after steroid withdrawal

  2003cites this paper
• Drug Interactions with Tacrolimus

  2002cites this paper
• Tacrolimus-induced nephrotoxicity unmasked by induction of the CYP3A4 system with St John's wort.

  2002cites this paper
• Drug interactions with tacrolimus.

  2002cites this paper
• A New Substrate Specificity for Acyl Transferase Domains of the Ascomycin Polyketide Synthase in Streptomyces hygroscopicus *

  2002cites this paper
• Immunosuppressive Therapy for Paediatric Transplant Patients

  2002cites this paper
• Covariate Effects on the Apparent Clearance of Tacrolimus in Paediatric Liver Transplant Patients Undergoing Conversion Therapy

  2001cites this paper
• THE EFFECT OF GUT METABOLISM ON TACROLIMUS BIOAVAILABILITY IN RENALTRANSPLANT RECIPIENTS1,2

  2001cites this paper
• Clinical influencing factors for daily dose, trough level, and relative clearance of tacrolimus in renal transplant recipients.

  2000cites this paper
• Therapeutic drug monitoring in solid-organ transplant recipients

  2000cites this paper
• Clinical study of FK 506 in renal transplant recipients.

  2000cites this paper
• Pharmacokinetics of intra-arterial delivery of tacrolimus to vascularly isolated rabbit forelimb.

  1999cites this paper
• Prophylaxis of renal transplant rejection with new chemical immunosuppressants (tacrolimus, mycophenolate mofetil, sirolimus): will these drugs make antibody induction superfluous?

  1999cites this paper
• Increased clearance of tacrolimus in children: need for higher doses and earlier initiation prior to bone marrow transplantation

  1999cites this paper
• Pharmacokinetic/pharmacodynamic analysis of tacrolimus-induced QT prolongation in guinea pigs.

  1999cites this paper
• Tacrolimus (FK 506).

  1999cites this paper
• Tacrolimus in liver transplantation.

  1999cites this paper
• Massive ingestion of tacrolimus in a young liver transplant patient.

  1998cites this paper
• Tacrolimus pharmacokinetics in BMT patients

  1998cites this paper
• Therapeutic Monitoring of Tacrolimus

  1998cites this paper
• Optimal time points for the prediction of the area-under-the-curve in liver transplant patients receiving tacrolimus.

  1998cites this paper
• Elimination of FK-506 by continuous hemodiafiltration in a liver transplant patient.

  1997cites this paper
• The evolution of immunosuppression with FK506 in pediatric living-related liver transplantation.

  1996cites this paper
• The Use of Therapeutic Drug Monitoring to Optimise Immunosuppressive Therapy

  1996cites this paper
• Suggested guidelines for the use of tacrolimus in pediatric liver transplant patients.

  1996cites this paper
• Clinical relevance of monitoring tacrolimus: comparison of microparticle enzyme immunoassay, enzyme-linked immunosorbent assay, and liquid chromatography mass spectrometry in renal transplant recipients converted from cyclosporine to tacrolimus.

  1996cites this paper
• Maintenance Immunosuppressive Drug Therapy and Potential Major Complications

  1996cites this paper
• Tacrolimus (FK506) in Thoracic Organ Transplantation

  1996cites this paper
• Clinical Pharmacokinetics of Tacrolimus

  1995cites this paper